9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
8 citations
,
January 2013 in “Medicinal chemistry” The compound 4c showed strong potential as an anticancer agent.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Biochanin A from soy is a promising and safe candidate for treating hair loss.
3 citations
,
June 2018 in “Bioorganic & medicinal chemistry” Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Biochanin A from soy is a promising and safe candidate for treating hair loss.
9 citations
,
April 2006 in “International Journal of Dermatology” DFMO may help control hair growth and treat cancer.
7 citations
,
January 1994 in “Annual Reports in Medicinal Chemistry” Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
97 citations
,
November 1986 in “Journal of Steroid Biochemistry” Antiandrogens affect androgen-dependent body functions and are used for various medical conditions, with some risks like fetus feminization, but new forms like 17α-propylmesterolone show promise for acne without systemic effects.
4 citations
,
January 2023 in “Marine Drugs” Marine compounds from gorgonians and soft corals show promise for drug development, especially for chronic disorders.
5 citations
,
January 2024 in “Egyptian Dental Journal /Egyptian Dental Journal” Anti-cancer drugs are diverse and hard to classify due to their different forms and actions.
119 citations
,
October 1992 in “Fundamental & Clinical Pharmacology” Potassium channel openers could help treat cardiovascular diseases and asthma but require better targeting to specific tissues for effective use.
6 citations
,
April 2014 in “European journal of medicinal chemistry” New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.
14 citations
,
April 1978 in “International Journal of Dermatology” Antiandrogens can treat acne, hirsutism, and seborrhea by reducing sebum production and androgen action.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
3 citations
,
January 2016 in “Recent Advances in Biology and Medicine” Smeathxanthone A improves wound healing and lowers blood sugar in diabetic mice.
May 2024 in “Reactions weekly” 21 citations
,
April 2016 in “International Journal of Oncology” GnRH treatment can reduce breast cancer cell invasion.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
50 citations
,
December 2006 in “Bone” Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.
16 citations
,
May 2006 in “PubMed” Alpha-melanocyte-stimulating hormone helps manage skin inflammation and protect against UV damage.
1 citations
,
April 2022 in “Cell Death Discovery” Increasing Smurf2 hinders hair follicle stem cell differentiation and wound healing.
April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.